You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Optimizing Treatment of Resistant/Refractory CMV Infection in Solid Organ Transplant Recipients

  • Authors: Camille Nelson Kotton, MD, FIDSA, FAST
  • CME / CE Released: 9/15/2022
  • Valid for credit through: 9/14/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™

    Nurses - 0.75 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)

    Pharmacists - 0.75 Knowledge-based ACPE (0.075 CEUs)

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This activity is intended for clinicians practicing in transplantation, infectious disease, and nephrology.

This activity is meant to improve clinician’s identification of resistant/refractory cytomegalovirus (CMV) and update them on newly approved treatment strategies for resistant/refractory CMV in solid organ transplant (SOT) patients. 

CMV is one of the most common opportunistic infections affecting solid organ transplant recipients (SOTRs), conveying higher risks of complications, graft loss, morbidity, and mortality. Treatment options for CMV are limited, have similar mechanisms of action, suffer from cross-resistance, and have serious toxicities. Until recently, no treatment option was available in the resistant/refractory setting. This workshop, developed in collaboration with The Transplantation Society (TTS) and Dr. Camille Kotton, MD, FIDSA, FAST, will take you through a CMV primer and then move on to discuss cases submitted by your peers from transplant centers across the United States.

Upon completion of this activity, participants should be better able to:

  • Employ evidence-based antiviral treatment strategies for cytomegalovirus (CMV) in solid organ transplant (SOT) patients
  • Utilize antiviral resistance testing to identify SOT patients with treatment refractory or drug resistant CMV
  • Implement new treatment strategies in the management of resistant or refractory CMV in SOT patients


RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty Affiliation and Disclosures

  • Camille Nelson Kotton, MD, FIDSA, FAST

    Clinical Director, Transplant and Immunocompromised Host Infectious Diseases 
    Infectious Diseases Division 
    Massachusetts General Hospital 
    Harvard Medical School 
    Boston, Massachusetts


    Camille Nelson Kotton, MD, FIDSA, FAST, has the following relevant financial relationships:
    Consultant or advisor for: Biotest; Evrys; Exevir; Hookipa; Merck; Oxford Immunotec; Roche Diagnostics; Takeda.

All of the relevant financial relationships listed for this individual have been mitigated according to RMEI policies.

Planners and Managers
All planners and managers have no relevant financial relationship(s) with ineligible companies.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Accreditation Statements

In support of improving patient care, this activity has been planned and implemented by RMEI Medical Education, LLC and The Transplantation Society. RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Contact This Provider

    For Nurses

  • The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours(s).

    Contact This Provider

    For Pharmacists

  • RMEI Medical Education, LLC designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
    (Universal Activity Number:  JA4008290-9999-22-001-H01-P)

    Type of Activity: Knowledge

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 80% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at [email protected].

Users must:

  • • Read the learning objectives and faculty disclosures
  • • Participate in the activity
  • • Complete the activity evaluation and attest to credit.

There is no fee to participate.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Optimizing Treatment of Resistant/Refractory CMV Infection in Solid Organ Transplant Recipients

Authors: Camille Nelson Kotton, MD, FIDSA, FASTFaculty and Disclosures

CME / CE Released: 9/15/2022

Valid for credit through: 9/14/2023


Pre-Assessment Survey

Before you begin, please take this brief survey.

  • Print